We are aware that coronavirus is only controlled with possible with the vaccine. Several countries around the world are making efforts to find this vaccine, and Oxford University's experiments are hopeful.
The experiments did on the monkeys have yielded good results. So far, six monkeys at rocky mountain laboratory have been examined for the past month. The scientist found that monkeys are healthy even after they are subjected to the virus.
As the tests on animals gave satisfactory results, they proceeded for the human trails. So far, 550 patients are injected with this vaccine and nearly 6000 will be injected by the end of May.
Serum Institute of India, which is partnering Oxford University said it is simultaneously initiating production of the vaccine in India with the hope that trials will be successful. The vaccine candidate called ChAdOx1 nCoV-19 is made from a virus (ChAdOx1).
"We are looking forward to building up 20-40 million doses by September-October. If successful, we will also make it available in as many countries as possible including India. Our Pune manufacturing facility has an investment of about â¹500-600 crore that we have already done for one of the other vaccines in the past. Besides, building a brand-new facility for the COVID 19 vaccine will take approximately 2-3 years," said Serum Institute of India chief executive officer Adar Poonawalla.
The experiments did on the monkeys have yielded good results. So far, six monkeys at rocky mountain laboratory have been examined for the past month. The scientist found that monkeys are healthy even after they are subjected to the virus.
As the tests on animals gave satisfactory results, they proceeded for the human trails. So far, 550 patients are injected with this vaccine and nearly 6000 will be injected by the end of May.
Serum Institute of India, which is partnering Oxford University said it is simultaneously initiating production of the vaccine in India with the hope that trials will be successful. The vaccine candidate called ChAdOx1 nCoV-19 is made from a virus (ChAdOx1).
"We are looking forward to building up 20-40 million doses by September-October. If successful, we will also make it available in as many countries as possible including India. Our Pune manufacturing facility has an investment of about â¹500-600 crore that we have already done for one of the other vaccines in the past. Besides, building a brand-new facility for the COVID 19 vaccine will take approximately 2-3 years," said Serum Institute of India chief executive officer Adar Poonawalla.